Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis
Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids
Sponsor: Mallinckrodt
Terminated
This trial was terminated. No reason was provided.
This PHASE4 trial investigates Uveitis and is currently terminated or withdrawn. Mallinckrodt leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
▶ Show 6 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Nov 2018 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mallinckrodt
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .